Table 1 Prevalence and incidence of rhGH treatment in SGA patients in Italy from 2011 to 2017, according to the National Registry of Growth Hormone therapy data
Year | |||||||||
|---|---|---|---|---|---|---|---|---|---|
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | Mean | ±DS | |
Prevalence | |||||||||
SGA treated patients (n) | 54 | 68 | 65 | 70 | 108 | 140 | 155 | ||
Prevalence (per 100,000 general population/year) | 0.37 | 0.47 | 0.44 | 0.28 | 0.22 | 0.27 | 0.37 | 0.35 | 0.09 |
Prevalence (per 100,000 0–15 years population/year) | 0.61 | 0.76 | 0.72 | 0.78 | 1.22 | 1.60 | 1.79 | 1.07 | 0.47 |
Incidence | |||||||||
New SGA treated patients (n) | 39 | 29 | 30 | 30 | 47 | 49 | 39 | ||
Incidence (per 100,000 general population/year) | 0.37 | 0.27 | 0.22 | 0.28 | 0.44 | 0.47 | 0.38 | 0.35 | 0.09 |
Incidence (per 100,000 0–15 years population/year) | 0.44 | 0.33 | 0.27 | 0.34 | 0.53 | 0.56 | 0.45 | 0.42 | 0.11 |